The Food and Drug Administration today published a notice seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and Mitigation Strategy. The proposal would require that certain solid oral dosage forms of immediate-release opioid analgesics commonly prescribed to treat acute pain be made available in fixed-quantity blister packaging for outpatient dispensing. “This could reduce the amount of unused opioid analgesics, thereby reducing opportunities for misuse, abuse, inappropriate access and overdose, and possibly reducing the development of new opioid addiction,” the agency said. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 allows the FDA to require special packaging for opioids and other drugs that pose a risk of abuse or overdose. 

Related News Articles

Headline
The Health Resources and Services Administration yesterday awarded 80 rural consortia $1 million each to help prevent, treat and support recovery for patients…
Headline
The National Association of Attorneys General yesterday urged congressional leaders to remove federal barriers to opioid use disorder treatment.
Headline
The number of naloxone prescriptions dispensed from retail pharmacies doubled in 2018, but access to the emergency opioid overdose treatment still varies…
Headline
The Department of Health and Human Services seeks input from health care providers and other stakeholders for a report to Congress on ensuring legitimate…
Headline
The Department of Health and Human Services yesterday sent Congress its plan to help states develop and expand innovative strategies to provide housing-related…
Headline
Qualified nonprofits and government agencies may submit through Aug. 25 letters of intent to apply for funding from the Foundation for Opioid Response Efforts…